FindTrial
Sign In

Total Marrow Irradiation

RADIATION19 trials

Sponsors

City of Hope Medical Center, Masonic Cancer Center, University of Minnesota, Ottawa Hospital Research Institute, Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Gliwice, University of Illinois at Chicago

Conditions

Acute Lymphoblastic LeukemiaAcute Lymphoblastic Leukemia in RemissionAcute Lymphocytic LeukemiaAcute Myeloid LeukemiaAcute Myeloid Leukemia in RemissionAdult Acute Lymphoblastic Leukemia in Complete RemissionAdult Acute Myeloid Leukemia With 11q23 (MLL) AbnormalitiesAdult Acute Myeloid Leukemia With Del(5q)

Phase 1

Melphalan and Radiation Therapy Followed By Lenalidomide in Treating Patients Who Are Undergoing Autologous Stem Cell Transplant for Stage I, Stage II, or Stage III Multiple Myeloma
CompletedNCT00112827
City of Hope Medical CenterRefractory Multiple Myeloma, Smoldering Multiple Myeloma, Stage III Multiple Myeloma +2
Start: 2004-11-30End: 2019-02-15Updated: 2025-06-06
MT2004-30: Tomotherapy for Solid Tumors
TerminatedNCT00623077
Masonic Cancer Center, University of MinnesotaBrain and Central Nervous System Tumors, Kidney Cancer, Liver Cancer +2
Start: 2005-08-31End: 2016-10-31Updated: 2017-12-05
Total Marrow Irradiation for Refractory Acute Leukemia
CompletedNCT00686556
Masonic Cancer Center, University of MinnesotaAcute Lymphoblastic Leukemia, Multiple Myeloma, Myelodysplastic Syndrome
Start: 2012-08-31End: 2016-12-31Updated: 2017-12-05
Total Marrow and Total Lymph Node Irradiation, Fludarabine, and Melphalan Followed By Donor Stem Cell Transplant in Treating Patients With Advanced Hematological Cancer That Has Not Responded to Treatment
TerminatedNCT00800150
City of Hope Medical CenterChronic Myeloproliferative Disorders, Leukemia, Lymphoma +3
Start: 2008-11-30End: 2010-10-31Updated: 2015-06-08
Total Marrow Irradiation & Autologous Stem Cell Transplantation for Relapsed or Refractory Myeloma
NCT00800059
Ottawa Hospital Research InstituteMultiple Myeloma
Start: 2008-11-30End: 2025-11-30Target: 27Updated: 2015-07-27
Bortezomib, Total Marrow Irradiation, Fludarabine Phosphate, and Melphalan in Treating Patients Undergoing Donor Peripheral Blood Stem Cell Transplant For High-Risk Stage I or II Multiple Myeloma
CompletedNCT01163357
City of Hope Medical CenterAutologous Hematopoietic Stem Cell Transplant Recipient, Loss of Chromosome 17p, Plasma Cell Leukemia +2
Start: 2011-01-28End: 2024-05-20Updated: 2025-03-26
TMI With HD Mel in ASCT for R/R Multiple Myeloma (BMT-03)
CompletedNCT02043847
University of Illinois at ChicagoMultiple Myeloma, Refractory to Standard Treatment, Multiple Myeloma, Relapsed
Start: 2014-01-14End: 2016-09-14Updated: 2024-11-13
Total Marrow Irradiation With High Dose Melphalan Prior to Autologous Transplant for Multiple Myeloma
TerminatedNCT02043860
University of Illinois at ChicagoMultiple Myeloma
Start: 2014-01-10End: 2016-11-07Updated: 2019-10-14
Targeted Marrow Irradiation, Fludarabine Phosphate, and Busulfan Before Donor Progenitor Cell Transplant in Treating Patients With Hematologic Malignancies
CompletedNCT02129582
Case Comprehensive Cancer CenterAcute Lymphocytic Leukemia, Acute Myeloid Leukemia, Chronic Lymphocytic Leukemia +8
Start: 2014-11-05End: 2020-03-05Updated: 2021-05-07
Intensity Modulated Total Marrow Irradiation, Fludarabine Phosphate, and Melphalan in Treating Patients With Relapsed Hematologic Cancers Undergoing a Second Donor Stem Cell Transplant
SuspendedNCT02333162
University of ChicagoPreviously Treated Myelodysplastic Syndrome, Recurrent Adult Acute Lymphoblastic Leukemia, Recurrent Adult Acute Myeloid Leukemia +1
Start: 2014-12-05End: 2028-12-01Target: 30Updated: 2026-03-30
Total Marrow and Lymphoid Irradiation and Chemotherapy Before Donor Transplant in Treating Patients With Myelodysplastic Syndrome or Acute Leukemia
CompletedNCT02446964
City of Hope Medical CenterAcute Myeloid Leukemia in Remission, Adult Acute Lymphoblastic Leukemia in Complete Remission, Childhood Acute Lymphoblastic Leukemia in Complete Remission +5
Start: 2015-06-25End: 2025-05-20Updated: 2025-06-22
Melphalan, Total Marrow Irradiation, and Autologous Stem Cell Transplantation in Treating Patients With High-Risk Multiple Myeloma
WithdrawnNCT03100877
City of Hope Medical CenterPlasma Cell Leukemia in Remission, Plasma Cell Myeloma
Start: 2018-01-31End: 2020-05-24Updated: 2017-12-13
Total Marrow and Lymphoid Irradiation Before Donor Transplant and Cyclophosphamide in Treating Patients With Acute Myeloid Leukemia
SuspendedNCT03467386
City of Hope Medical CenterAcute Myeloid Leukemia
Start: 2018-03-19End: 2026-09-06Updated: 2026-02-17
Total Marrow and Lymphoid Irradiation, Fludarabine, and Melphalan Before Donor Stem Cell Transplant in Treating Participants With High-Risk Acute Leukemia or Myelodysplastic Syndrome
SuspendedNCT03494569
City of Hope Medical CenterAcute Lymphoblastic Leukemia, Acute Lymphoblastic Leukemia in Remission, Acute Myeloid Leukemia +5
Start: 2018-07-06End: 2026-06-11Target: 36Updated: 2026-03-18
90Y-DOTA-anti-CD25 Basiliximab, Fludarabine, Melphalan, and Total Marrow and Lymphoid Irradiation for the Treatment of High-Risk Acute Leukemia or Myelodysplastic Syndrome
Active, not recruitingNCT05139004
City of Hope Medical CenterAcute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Myelodysplastic Syndrome +1
Start: 2022-07-19End: 2027-06-13Updated: 2025-07-08

Phase 2

Total Marrow Irradiation and High-dose Melphalan for Double Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma
NCT01665014
Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, GliwiceMultiple Myeloma
Start: 2012-08-31End: 2016-08-31Target: 50Updated: 2012-08-17
Total Marrow and Lymphoid Irradiation and Chemotherapy Before DSCT in Treating Patients With High-Risk ALL or AML
Active, not recruitingNCT02094794
City of Hope Medical CenterAdult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q), Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) +7
Start: 2014-05-12End: 2026-05-26Updated: 2025-07-18
Study of Intensity Modulated Total Marrow Irradiation (IM-TMI) in Addition to Fludarabine/Busulfan Conditioning for Allogeneic Transplantation in High Risk AML and Myelodysplastic Syndromes
Active, not recruitingNCT03121014
University of Illinois at ChicagoAcute Myeloid Leukemia, Myelodysplastic Syndromes
Start: 2017-04-24End: 2026-04-30Target: 38Updated: 2026-01-13
Efficacy and Safety of UCBT With TMI -Based Conditioning Regimen for Adults With Refractory/Relapsed Aplastic Anemia
Not yet recruitingNCT07078721
Institute of Hematology & Blood Diseases Hospital, ChinaAplastic Anemia Idiopathic
Start: 2025-07-20End: 2028-06-30Target: 11Updated: 2025-07-22

Related Papers

Total marrow irradiation-based, intensified reduced-intensity conditioning regimen for haploidentical hematopoietic cell transplantation with posttransplant cyclophosphamide: A prospective study
Blood2025-11-03
Total marrow and lymphoid irradiation (TMLI) with fludarabine-melphalan (FM) conditioning for matched donor hematopoietic cell transplant (HCT) in older patients with Relapsed/Refractory (R/R) disease
Blood2025-11-03
Total marrow irradiation-based, intensified reduced-intensity conditioning regimen for hematopoietic cell transplantation in patients aged 60 years or older: A prospective study
Blood2025-11-03
Total marrow and lymphoid irradiation (2000 cGy) together with cyclophosphamide and etoposide prior to allogeneic hematopoietic cell transplantation is an effective regimen for Relapsed/Refractory leukemia, with low non-relapse mortality
Blood2025-11-03
First-in-human phase I trial combining radiopharmaceutical therapy (RPT) using a 90y-anti-CD25 monoclonal antibody (Mab) with total marrow and lymphoid irradiation (TMLI) in relapsed or refractory (R/R) acute leukemia
Blood2025-11-03
Intensified conditioning with high-dose total marrow irradiation and myeloablative chemotherapy reduces risk of relapse without increasing toxicity in allogeneic hematopoietic stem cell transplant for high-risk myeloid malignancies: a phase II study
Haematologica2025-06-19
Addition of Myeloablative Doses of Total Marrow Irradiation (TMI) to Myeloablative Fludarabine/Busulfan Conditioning for Allogeneic HSCT in Patients with High-Risk AML, CML, or Myelodysplastic Syndrome: A Phase II Clinical Trial
Blood2023-11-02
Total Marrow and Lymphoid Irradiation (TMLI) -Based Conditioning Regimen in Patients with Acute Leukemia Undergoing Allogeneic Hematopoietic Cell Transplant with Measurable Residual Disease
Blood2023-11-02
Total Marrow and Lymphoid Irradiation (TMLI) at a Dose of 2000cGy in Combination with Post-Transplant Cyclophosphamide (PTCy)-Based Graft Versus Host Disease (GvHD) Prophylaxis Is Safe and Associated with Favorable GvHD-Free/Relapse-Free Survival at 1 Year in Patients with Acute Myeloid Leukemia (AML)
Blood2020-11-043 citations
Phase I Trial of a Novel Conditioning Regimen Utilizing Total Marrow Irradiation (TMI) with Fludarabine-Melphalan for Patients with Relapsed Hematologic Malignancies Undergoing Second Allogeneic Stem Cell Transplantation (Allo-SCT)
Blood2020-11-04
A phase 1 trial of autologous stem cell transplantation conditioned with melphalan 200 mg/m<sup>2</sup>and total marrow irradiation (TMI) in patients with relapsed/refractory multiple myeloma
Leukemia & lymphoma/Leukemia and lymphoma2017-10-2524 citations
Total marrow irradiation (TMI) with helical tomotherapy and peripheral blood progenitor cell rescue (PBPC) following high-dose melphalan (Mel) and PBPC as part of tandem autologous transplant (TAT) for patients with multiple myeloma.
Journal of Clinical Oncology2015-05-203 citations
Napromienianie szpiku całego ciała — prezentacja metody
Nowotwory Journal of Oncology2014-09-011 citations